Search - tctmd.com

Displaying 1 - 20 of 62

Sort: Relevancy | Date

News Daily News

Side Effects of Statins Might Be Overstated: CTT Collaboration

Michael O'Riordan

February 12, 2026

News Opinion CV Team Dispatch

January 2026 Dispatch for the CV Team

L.A. McKeown

January 16, 2026

News Daily News

Oral Semaglutide Gets FDA Approval for CV Event Reduction in High-risk Diabetes Patients

Caitlin E. Cox

October 22, 2025

News Daily News

Evolocumab Gains Expanded Indication for Primary Prevention

Michael O'Riordan

August 26, 2025

News Daily News

Inclisiran Gains Indication as Stand-alone Therapy to Reduce LDL Cholesterol

Michael O'Riordan

August 06, 2025

News Daily News

FDA Approves Finerenone for HF Patients With Mildly Reduced or Preserved EF

Caitlin E. Cox

July 14, 2025

News Daily News

FDA Approves Triple Therapy Polypill for High Blood Pressure

Michael O'Riordan

June 10, 2025

News Daily News

FDA Approves TAVI for Asymptomatic Patients With Severe Aortic Stenosis

Michael O'Riordan

May 01, 2025

News Daily News

Coverage and Use of Impella and Watchman: A Tale of Four Countries

Michael O'Riordan

March 04, 2025

News Daily News

Little Pre- and Postmarket Testing for Most Recalled CV Devices

Michael O'Riordan

September 16, 2024

News Opinion CV Team Dispatch

June 2024 Dispatch for the CV Team

L.A. McKeown

June 01, 2024

News Daily News

Bempedoic Acid Gains CV Risk Reduction Indication

Todd Neale

March 22, 2024

News Daily News

FDA Grants MACE Reduction Indication for Semaglutide

Todd Neale

March 08, 2024

News Daily News

Mechanism’s Mojo: ‘Obvious’ CV Therapies More Likely to Be Seen as Effective

Michael O'Riordan

February 23, 2024

News Daily News

Symplicity Spyral Approved: FDA Clears Second Renal Denervation System

Todd Neale

November 20, 2023

News Daily News

FDA Approves First Extravascular ICD

Yael L. Maxwell

October 23, 2023

News Daily News

FDA Approves Colchicine for Decreasing CV Events

Caitlin E. Cox

June 20, 2023

News Daily News

FDA Extends Dapagliflozin Indication Across LVEF Spectrum

Shelley Wood

May 09, 2023

News Daily News

Medical Devices Cleared on Faulty Predicates More Likely to be Recalled

Michael O'Riordan

January 17, 2023

News Daily News

Higher Annual TAVI Volumes Linked to Greater Use of Embolic Protection

L.A. McKeown

August 23, 2022

Advertisement

Side Effects of Statins Might Be Overstated: CTT Collaboration

January 2026 Dispatch for the CV Team

Oral Semaglutide Gets FDA Approval for CV Event Reduction in High-risk Diabetes Patients

Evolocumab Gains Expanded Indication for Primary Prevention

Inclisiran Gains Indication as Stand-alone Therapy to Reduce LDL Cholesterol

FDA Approves Finerenone for HF Patients With Mildly Reduced or Preserved EF

FDA Approves Triple Therapy Polypill for High Blood Pressure

FDA Approves TAVI for Asymptomatic Patients With Severe Aortic Stenosis

Coverage and Use of Impella and Watchman: A Tale of Four Countries

Little Pre- and Postmarket Testing for Most Recalled CV Devices

June 2024 Dispatch for the CV Team

Bempedoic Acid Gains CV Risk Reduction Indication

FDA Grants MACE Reduction Indication for Semaglutide

Mechanism’s Mojo: ‘Obvious’ CV Therapies More Likely to Be Seen as Effective

Symplicity Spyral Approved: FDA Clears Second Renal Denervation System

FDA Approves First Extravascular ICD

FDA Approves Colchicine for Decreasing CV Events

FDA Extends Dapagliflozin Indication Across LVEF Spectrum

Medical Devices Cleared on Faulty Predicates More Likely to be Recalled

Higher Annual TAVI Volumes Linked to Greater Use of Embolic Protection

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content